

## **Louisiana Medicaid Shared Plans and Legacy Medicaid Pharmacy Policy Change**

### Therapeutic Duplication of Short-Acting Beta<sub>2</sub> Agonist Inhalers (Albuterol, Levalbuterol, and Pirbuterol Inhalers)

Effective October 1, 2013, pharmacy claims billed for concurrent use of different short-acting beta<sub>2</sub> agonist inhalers (SABAs) will deny with a therapeutic duplication. When a patient has an active prescription for a SABA, an incoming claim for a different SABA will deny with:

**NCPDP rejection code 88 (DUR Reject Error) mapped to**

**EOB code 482 (Therapeutic Duplication)**

After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. This consultation is necessary to confirm that (1) the prescriber is aware of the current active SABA claim and (2) the addition of a different SABA is necessary (i.e., a change in therapy). To bill concurrent therapy with different SABAs, the pharmacist must document the codes on the hardcopy prescription and submit the override in:

<b>NCDPD 439-E4 field (Reason for Service code)</b>	<b>TD (Therapeutic Duplication)</b>
<b>NCDPD 439-E4 field (Professional Service code)</b>	<b>M0 (Prescriber Consulted)</b>
<b>NCPDP 441-E6 field (Result of Service Code)</b>	<b>1G (Filled with Prescriber Approval)</b>